ClinicalTrials.gg
RecruitingNCT06819891SIBERITE-2Updated Oct 26, 2026

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

A Phase 3 interventional study of Afimkibart and Placebo in Moderately to Severely Active Crohns Disease, sponsored by Hoffmann-La Roche. Recruiting at 208 sites in 27 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 26, 2026Site recruiting status changed11 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
425
Allocation
Randomized
Ages
16 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Crohn Disease by Hoffmann-La Roche — 3 open to participants now, 4 under way, 3 of them phase 3. Crohn Disease · Hoffmann-La Roche.

Planned enrollment
4th of 10
425 · median 122
Started
2025
with 1 other
Phase 3
5 of 10
3 open now
Registered
8th of 10
by date

Among the 10 studies in Crohn Disease by Hoffmann-La Roche, this one is the 4th largest by planned enrollment, is one of 2 that started in 2025, is one of 5 in phase 3, and was the 8th registered.

Crohn Disease

1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.

Browse Crohn Disease studies →

Open to participants now

3 of the 10 studies in Crohn Disease by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.

This study: 16 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Crohn Disease by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).

03

Conditions studied

  • Moderately to Severely Active Crohns Disease

Browse trials for

04

Who can participate

Ages eligible
16 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CD
  • Moderately to severely active CD
  • Bodyweight >= 40 kilogram (kg)
  • Demonstrated inadequate response, loss of response and/or intolerance to at least one protocol-specified conventional or advanced CD therapy
  • Males and females of must meet protocol criteria for requirements

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of ulcerative colitis (UC) or indeterminate colitis, ischemic colitis, infectious colitis, radiation colitis, microscopic colitis
  • Participant with a history of >= 3 bowel resections (> 2 missing segments of the 5 following segments: terminal ilelium, right colon, transverse colon, sigmoid and left colon, and rectum)
  • Diagnosis of short gut or short bowel syndrome
  • Presence of an ileostomy, colostomy or ileoanal pouch
  • Participants with symptomatic bowel strictures, fulminant colitis, or toxic megacolon
  • Presence of abdominal or perianal abscess
  • Presence of rectovaginal, enterovaginal, high output enterocutaneous fistula, enterovesical fistulas or perianal fistulas with >3 openings
  • Participants with symptomatic bowel strictures, fulminant colitis, or toxic megacolon
  • Current diagnosis or suspicion of primary sclerosing cholangitis
  • Pregnancy or breastfeeding, or intention of becoming pregnant during the study
  • Any past or current evidence of cancer of gastrointestinal tract, high-grade colonic dysplasia and participants with low-grade dysplasia are eligible if lesions have been completely removed
  • History of non-gastrointestinal cancer, with the exception of adequately treated non- basal cell or squamous cell skin cancer or in situ cervical cancer
  • Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), (HIV), (HBV), (HCV) during screening
  • Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB
  • Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
425 participants (estimated)

Study arms

  • Experimental
    Afimkibart

    Participants will receive afimkibart intravenously (IV) followed by afimkibart subcutaneous (SC) injection.

    Drug: Afimkibart

  • Placebo comparator
    Placebo

    Participants will receive placebo IV followed by afimkibart SC injection.

    Drug: Placebo

Interventions

  • Afimkibart will be administered as IV infusion. Afimkibart will be administered as SC injection.

    Also known as: PF-06480605, RVT-3101, RG6631, RO7790121

  • DrugPlacebo

    Placebo matching IV afimkibart.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Clinical Remission per Crohn's Disease Activity Index (CDAI) Score

    Percentage of participants achieving a CDAI score of \<150. The index is a weighted sum of scores on eight components: number of liquid or soft stools (stool frequency), abdominal pain, general well-being, number of complications, use of anti-diarrheal medication, presence of an abdominal mass, hematocrit, and percentage deviation from standard body weight. CDAI generally ranges from 0 to roughly 600, with higher values indicating greater activity.

    Time frame: At Week 12

  2. Percentage of Participants with Endoscopic Response

    Percentage of participants achieving a decrease in Simple Endoscopic Score for Crohn's Disease (SES-CD) of \>50% from baseline. The SES-CD is a composite of four features of endoscopic activity (presence and size of ulcers, extent of ulcerated surface, extent of affected and presence and type of narrowings or stenosis) in up to five ileocolonic segments (terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum). Each feature is scored on a scale from 0 to 3, giving segment subscores of 0 to 12 points and a total SES-CD range of 0-60, with a higher value indicating greater severity.

    Time frame: At Week 12

Secondary outcomes

  1. Percentage of Participants with Symptomatic Remission

    Percentage of participants with the daily number of liquid or very soft stools \<=2.8 and the average of daily abdominal pain scores in the past week \<=1, with neither being greater than baseline.

    Time frame: At Week 12

  2. Percentage of Participants with Endoscopic Remission

    Percentage of participants with an SES-CD of 0 to 4 with a decrease from baseline \>=2 and no subscore \>1.

    Time frame: At Week 12

  3. Percentage of Participants with Ulcer-free Endoscopy

    Percentage of participants with an SES-CD ulcerated surface subscore of 0.

    Time frame: At Week 12

  4. Average of Daily Number of Liquid or Very Soft Stools in the Past Week (SF)

    Daily average number of liquid or very soft stools over 7 days.

    Time frame: Baseline through Week 12

  5. Average of Daily Abdominal Pain Scores in the Past Week (APS)

    The average daily rating of abdominal pain in the past 7 days. The pain is assessed on a scale of 0-3 with 0 indicating no pain and 3 indicating severe pain.

    Time frame: Baseline through Week 12

  6. Bowel Urgency

    Bowel urgency from baseline through week 12 and. Bowel urgency is a single-item self-reported assessment of sudden or immediate need to have a bowel movement in the past 24 hours. The item response is reported on a 4-point Likert scale, from "None" to "Severe."

    Time frame: Baseline to Week 12

  7. Fatigue

    Fatigue, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), from baseline to Week 12. FACIT-F is a 13-item self-reported assessment of fatigue. Each item response option indicates the degree to which a given statement describing the level or impact of fatigue applies in the past 7 days. Response options are graded on a 5-point Likert-type scale, from "Not at all" to "Very much."

    Time frame: Baseline to Week 12

  8. Inflammatory Bowel Disease Questionnaire (IBDQ) Score

    Change in IBDQ score from baseline to week 12. The IBDQ is a 32-item questionnaire that measures four domains: bowel symptoms (10 questions); systemic symptoms (5 questions); emotional function (12 questions); and social function (5 questions). The total score ranges from 32-224, with a higher score indicating a better quality of life.

    Time frame: Baseline to Week 12

  9. Percentage of Participants with Clinical Remission: Among Biomarker-Defined Subgroups of Participants

    Percentage of participants achieving a CDAI score of \<150 at Week 12 in biomarker-defined subgroups. The index is a weighted sum of scores on eight components: number of liquid or soft stools (stool frequency), abdominal pain, general well-being, number of complications, use of anti-diarrheal medication, presence of an abdominal mass, hematocrit, and percentage deviation from standard body weight. CDAI generally ranges from 0 to roughly 600, with higher values indicating greater activity.

    Time frame: At Week 12

  10. Percentage of Participants with Endoscopic Response: Among Biomarker-Defined Subgroups of Participants

    Percentage of participants achieving a decrease in SES-CD of \>50% from baseline. The SES-CD is a composite of four features of endoscopic activity (presence and size of ulcers, extent of ulcerated surface, extent of affected and presence and type of narrowings or stenosis) in up to five ileocolonic segments (terminal ileum, right colon, transverse colon, sigmoid and left colon, and rectum). Each feature is scored on a scale from 0 to 3, giving segment subscores of 0 to 12 points and a total SES-CD range of 0-60, with a higher value indicating greater severity.

    Time frame: At Week 12

  11. Percentage of Participants with Clinical Response

    Percentage of participants with a decrease \>=100 in CDAI from baseline.

    Time frame: At Week 12

  12. Percentage of Participants with Symptomatic Response

    Percentage of participants with a decrease \>=30% in both SF and APS, with neither being greater than baseline.

    Time frame: At Week 12

  13. Overall Change in CD Symptoms

    Overall change in CD symptoms, as measured by the Patient Global Impression of Change (PGIC) from baseline to Weeks 2, 6 and 12. PGIC measures overall change in Crohn's disease symptoms from "Much better" to "Much worse".

    Time frame: Baseline to Weeks 2, 6 and 12

  14. Overall Severity in CD Symptoms

    Overall severity in CD symptoms, as measured by the Patient Global Impression of Severity (PGIS) from baseline to Weeks 2, 6 and 12. PGIS measures severity of Crohn's disease symptoms from "None" to "Very severe".

    Time frame: Baseline to Weeks 2, 6 and 12

  15. Change in General Well-being

    The average daily rating of general well-being in the past 7 days. Well-being is assessed on a scale of 0-4 with 0 indicating generally well and 4 indicating terrible.

    Time frame: Baseline through Week 12

  16. Incidence and Severity of Adverse Events (AEs)

    Incidence and severity of AEs, including serious AEs, AEs leading to treatment discontinuation and AEs of special interest.

    Time frame: Up to 30 Weeks after Baseline

  17. Presence of Draining Fistulas

    Fistulas will be assessed for draining or closed status, where closed fistulas will be assessed by the investigator as no longer draining.

    Time frame: Baseline through Week 12

07

Study locations

198 of 208 sites recruiting
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
    Recruiting
  • Sun City Clinical Research
    Glendale, Arizona 85304, United States
    Recruiting
  • Om Research LLC
    Lancaster, California 93534, United States
    Recruiting
  • Hoag Memorial Hospital Presbyterian;Hoag Center for Research and Education
    Newport Beach, California 92663, United States
    Recruiting
  • Empire Clinical Research
    Pomona, California 91767, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Stanford Medicine Outpatient Center
    Redwood City, California 94063, United States
    Recruiting
  • Clinical Applications Laboratories, Inc.
    San Diego, California 92103, United States
    Recruiting
  • Amicis Research Center
    Santa Clarita, California 91355, United States
    Recruiting
  • Peak Gastroenterology Associates
    Colorado Springs, Colorado 80907, United States
    Recruiting
  • J&A Clinical Research
    Doral, Florida 33126, United States
    Recruiting
  • Auzmer Research
    Lakeland, Florida 33813, United States
    Recruiting
  • Galenus Group Inc
    Lehigh Acres, Florida 33936, United States
    Recruiting
  • Homestead Associates in Research, Inc.
    Miami, Florida 33033, United States
    Recruiting
  • Allied Biomedical Research Institute, Inc
    Miami, Florida 33155, United States
    Recruiting
  • Rejuvaline Medical Research
    Miami, Florida 33155, United States
    Recruiting
  • Miami Beach Clinical Research Center
    Miami Beach, Florida 33141, United States
    Recruiting
  • Eminat Research Group
    Miramar, Florida 33027, United States
    Recruiting
  • Digestive and Liver Center of Florida
    Orlando, Florida 32825, United States
    Recruiting
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
    Recruiting
  • Santos Research Center, CORP
    Tampa, Florida 33615, United States
    Recruiting
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
    Recruiting
  • Morehouse School Of Medicine
    Atlanta, Georgia 30310-1495, United States
    Recruiting
  • The University of Chicago
    Chicago, Illinois 60637, United States
    Recruiting
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
    Recruiting
  • Robley Rex VA Medical Center
    Louisville, Kentucky 40206, United States
    Recruiting
  • One GI: GHP - Gastroenterology Health Partners Louisville
    Louisville, Kentucky 40218, United States
    Recruiting
  • Baton Rouge General Medical Center
    Baton Rouge, Louisiana 70809, United States
    Recruiting
  • Louisiana Research Center - GastroIntestinal Associates
    Shreveport, Louisiana 71105, United States
    Recruiting
  • Mercy Medical Center
    Baltimore, Maryland 21202, United States
    Recruiting
  • FOMAT Medical Research - Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
    Recruiting
  • University of Massachusetts Memorial Medical Center
    North Worcester, Massachusetts 01655, United States
    Recruiting
  • Gastroenterology Associates of Western Michigan, P.L.C.
    Wyoming, Michigan 49519, United States
    Recruiting
  • Gastrointestinal Associates Research
    Flowood, Mississippi 39232, United States
    Recruiting
  • Va Heartland Network - Harry S. Truman Memorial Veterans' Hospital
    Columbia, Missouri 65201-5275, United States
    Recruiting
  • Specialists in Gastroenterology
    St Louis, Missouri 63141, United States
    Recruiting
  • Dartmouth-Hitchcock Medical Center-Norris Cotton Cancer Center
    Lebanon, New Hampshire 03756, United States
    Recruiting
  • Virtua Crohns and Colitis Center
    Moorestown, New Jersey 08057, United States
    Recruiting
  • Robert Wood Johnson University Hospital
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • Ellipsis Research Group
    Brooklyn, New York 11215, United States
    Recruiting
  • Intercity Gastroenterology
    Fresh Meadows, New York 11366, United States
    Recruiting
  • NYU Langone Long Island Clinical Research Associates
    Lake Success, New York 11042, United States
    Recruiting
  • James J Peters Veterans Affairs Medical Center
    The Bronx, New York 10468, United States
    Recruiting
  • Digestive Disease Medicine of Central New York
    Utica, New York 13502, United States
    Recruiting
  • Charlotte Gastroenterology and Hepatology, P.L.L.C
    Charlotte, North Carolina 28207, United States
    Recruiting
  • Peters Medical Research (PMR), LLC
    High Point, North Carolina 27260, United States
    Recruiting
  • Clinical Inquest Center
    Beavercreek, Ohio 45431, United States
    Recruiting
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Recruiting
  • University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
  • University Gastroenterology
    Providence, Rhode Island 02904, United States
    Recruiting
  • Gastro One
    Cordova, Tennessee 38018, United States
    Recruiting
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37212-1375, United States
    Recruiting
  • University of Texas Southwestern Medical Center - Multidisciplinary Spine Clinic - James W. Aston Ambulatory Care Center
    Dallas, Texas 75390-8565, United States
    Recruiting
  • GI Alliance - Fort Worth
    Fort Worth, Texas 76104, United States
    Recruiting
  • GI Alliance
    Garland, Texas 75044, United States
    Recruiting
  • Integrity Advanced Therapeutics PLLC
    Houston, Texas 77090, United States
    Recruiting
  • Texas Digestive Disease Consultants-Lubbock powered by GI Alliance
    Lubbock, Texas 79410, United States
    Recruiting
  • Carta - Clinical Associates In Research Therapeutics Of America;LLC
    San Antonio, Texas 78212, United States
    Recruiting
  • Tyler Research Institute, LLC
    Tyler, Texas 75701, United States
    Recruiting
  • University of Texas Health Center at Tyler
    Tyler, Texas 75708, United States
    Recruiting
  • TDDC GI Alliance research Webster
    Webster, Texas 77598, United States
    Recruiting
  • GI Alliance-Richmond
    Richmond, Virginia 23229, United States
    Recruiting
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
    Recruiting
  • Washington Gastroenterology
    Tacoma, Washington 98405, United States
    Recruiting
  • University Physicians and Surgeons Inc, dba Marshall Health
    Huntington, West Virginia 25701, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Instituto Medico CER
    Quilmes, B1878DVB, Argentina
    Recruiting
  • CICE 9 de Julio
    San Miguel de Tucumán, T4000DPK, Argentina
    Recruiting
  • Macquarie University Hospital
    Macquarie Park, New South Wales 2109, Australia
    Recruiting
  • Sydney Adventist Hospital
    Wahroonga, New South Wales 2076, Australia
    Recruiting
  • Coral Sea Clinical Research Institute
    Mackay, Queensland 4740, Australia
    Withdrawn

    Not enrolling at this site — choose another above.

  • Lyell McEwin Hospital
    Adelaide, South Australia 5112, Australia
    Recruiting
  • Footscray Hospital
    Footscray, Victoria 3011, Australia
    Recruiting
  • Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
    Recruiting
  • Ordensklinikum Linz Barmherzige Schwestern
    Linz, 4010, Austria
    Recruiting
  • Klinikum Wels-Grieskirchen
    Wels, 4600, Austria
    Recruiting
  • CHU St Pierre (St Pierre)
    Brussels, 1000, Belgium
    Recruiting
  • UZ Brussel
    Brussels, 1090, Belgium
    Recruiting
  • Cliniques Universitaires St-Luc
    Brussels, 1200, Belgium
    Recruiting
  • Instituto Lobus Unimed Volta Redonda
    Volta Redonda, Rio de Janeiro 27258-000, Brazil
    Recruiting
  • Hospital Moinhos de Vento
    Porto Alegre, Rio Grande do Sul 90035-000, Brazil
    Recruiting
  • Newdata Clinical Trials
    Aracaju, Sergipe 49055-000, Brazil
    Recruiting
  • CECIP - Centro de Estudos Clínicos do Interior Paulista
    Jaú, São Paulo 17210-190, Brazil
    Recruiting
  • Hospital de Base de Sao Jose do Rio Preto
    São José do Rio Preto, São Paulo 15090-000, Brazil
    Recruiting
  • Hospital Sírio-Libanês
    São Paulo, São Paulo 01308-050, Brazil
    Withdrawn

    Not enrolling at this site — choose another above.

  • Multiprofile Hospital for Active Treatment Uni Hospital;Department of Gastroenterology.
    Panagyurishte, 4500, Bulgaria
    Recruiting
  • MC " Sveti Ivan Rilski Chudotvorets- 2010
    Plovdiv, 4003, Bulgaria
    Recruiting
  • Barrie GI Associates
    Barrie, Ontario L4M 7G1, Canada
    Recruiting
  • GNRR Digestive Clinics and Research Center Inc.
    Brampton, Ontario L6S 0E2, Canada
    Recruiting
  • London Health Sciences Centre Uni Campus
    London, Ontario N6A 5A5, Canada
    Withdrawn

    Not enrolling at this site — choose another above.

  • LDDI Clinical Trials Inc.
    London, Ontario N6K 1M6, Canada
    Recruiting
  • Toronto Immune and Digestive Health Institute
    North YORK, Ontario M6A 3B4, Canada
    Recruiting
  • CIUSSS de l Est de l Ile de Montreal - Hopital Maisonneuve Rosemont
    Montreal, Quebec H1T 2M4, Canada
    Recruiting
  • Medicina de Precisión - Celerity
    Las Condes, 7560908, Chile
    Recruiting
  • Medwal
    Santiago, 7500000, Chile
    Recruiting
  • Centro de Investigación Clínica UC-CICUC
    Santiago, 8330034, Chile
    Recruiting
  • First Affiliated Hospital of Gannan Medical University
    Ganzhou, Jiangxi 341000, China
    Recruiting
  • Jinhua municipal central hospital
    Jinhua, Zhejiang 321013, China
    Recruiting
  • Beijing Union Hospital
    Beijing, 100730, China
    Recruiting
  • Sichuan Provincial People's Hospital
    Chengdu, 610072, China
    Recruiting
  • Guangzhou First People's Hospital
    Guangzhou, 510180, China
    Recruiting
  • Zhujiang Hospital, Southern Medical University
    Guangzhou, 510280, China
    Recruiting

Showing the first 100 of 208 sites across 27 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Dec 2028, 43 months after the start.

Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's planned 43 months is close to that.

Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2025
First posted
Feb 11, 2025
StartActual
May 12, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
Apr 30, 2033
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
11 sites added, 2 sites removed. 4 sites changed recruiting status (4 now withdrawn)
Show 4 sites
  • University Physicians and Surgeons Inc, dba Marshall Health · Huntington, United StatesRecruiting→Withdrawn
  • Hospital Sírio-Libanês · São Paulo, BrazilRecruiting→Withdrawn
  • Clínica de la Mujer · Bogotá, ColombiaRecruiting→Withdrawn
  • Shree Giriraj Multispeciality Hospital · Rajkot, IndiaRecruiting→Withdrawn
Show 11 added (5 United States, 2 China, 1 Colombia, 1 Poland, 1 Australia, 1 United Kingdom)
  • NYU Langone Long Island Clinical Research Associates · Lake Success, United States
  • Huai'an First People's Hospital · Huai'an, China
  • The First Affilliated Hospital of Kunming Medical University · Kunming, China
  • Fundacion Cardiovascular de Colombia - KM 7 Autopista · Piedecuesta, Colombia
  • Nowe Zdrowie-CK Kieltucki I Wspolnicy Sp. j. · Staszów, Poland
  • FOMAT Medical Research - Chevy Chase Clinical Research · Chevy Chase, United States
  • Tyler Research Institute, LLC · Tyler, United States
  • Virginia Mason Medical Center · Seattle, United States
  • Washington Gastroenterology · Tacoma, United States
  • Lyell McEwin Hospital · Adelaide, Australia
  • Royal Victoria Infirmary · Newcastle upon Tyne, United Kingdom
Show 2 removed
  • The First Affilliated Hospital of Kunming Medical University · Kunming, China
  • Chevy Chase Clinical Research · Chevy Chase, United States
across 2 updates, Sep 28, 2026 – Oct 26, 2026
Show all 2 updates
  1. Oct 26, 2026
    6 sites added, 1 site removed. Shree Giriraj Multispeciality Hospital is now Withdrawn
    Show 6 added (4 United States, 1 Australia, 1 United Kingdom)
    • FOMAT Medical Research - Chevy Chase Clinical Research · Chevy Chase, United States
    • Tyler Research Institute, LLC · Tyler, United States
    • Virginia Mason Medical Center · Seattle, United States
    • Washington Gastroenterology · Tacoma, United States
    • Lyell McEwin Hospital · Adelaide, Australia
    • Royal Victoria Infirmary · Newcastle upon Tyne, United Kingdom
    Show 1 removed
    • Chevy Chase Clinical Research · Chevy Chase, United States
    + 1 other change: verification date
  2. Sep 28, 2026
    5 sites added, 1 site removed. 3 sites changed recruiting status (3 now withdrawn)
    Show 3 sites
    • University Physicians and Surgeons Inc, dba Marshall Health · Huntington, United StatesRecruiting→Withdrawn
    • Hospital Sírio-Libanês · São Paulo, BrazilRecruiting→Withdrawn
    • Clínica de la Mujer · Bogotá, ColombiaRecruiting→Withdrawn
    Show 5 added (2 China, 1 United States, 1 Colombia, 1 Poland)
    • NYU Langone Long Island Clinical Research Associates · Lake Success, United States
    • Huai'an First People's Hospital · Huai'an, China
    • The First Affilliated Hospital of Kunming Medical University · Kunming, China
    • Fundacion Cardiovascular de Colombia - KM 7 Autopista · Piedecuesta, Colombia
    • Nowe Zdrowie-CK Kieltucki I Wspolnicy Sp. j. · Staszów, Poland
    Show 1 removed
    • The First Affilliated Hospital of Kunming Medical University · Kunming, China
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06819891
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Feb 11, 2025
Start date
May 12, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
Apr 30, 2033 (estimated)
Last update
Oct 26, 2026

Study contacts

Reference Study ID Number: GA45332 https://forpatients.roche.com/ No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afimkibart

Start the discussion